AscellaHealth Launches Q2 2025 Specialty & Rare Pipeline Digest™ to Support Stakeholders Navigating Specialty Drug Growth
Globe Newswire • Thu Jul 10 2025
BERWYN, Pa., July 10, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, announces the release of its Q2 2025 Specialty & Rare Pipeline Digest™.
BERWYN, Pa., July 10, 2025 (GLOBE NEWSWIRE) – AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, announces the release of its Q2 2025 Specialty & Rare Pipeline Digest™. As the industry’s most comprehensive digital resource, this complimentary quarterly publication provides stakeholders with critical, up-to-date information on new, pending and upcoming specialty and rare disease drug launches and approvals, biosimilars and cell and gene therapies (CGTs). Designed to support stakeholders amid the accelerating pace of specialty drug approvals, the Digest delivers timely insights that enable proactive management and strategic utilization of emerging therapies.
To read more, click here
About AscellaHealth
Healthcare today is more complex than ever—especially when it comes to therapies for people living with rare and chronic conditions. These high-cost, high-impact treatments account for only a small fraction of prescriptions, but they make up the largest and fastest-growing share of total drug spend. As a result, balancing affordability and quality of care remains a significant challenge.
We’re here to change that.
Because at AscellaHealth, we believe that all patients in need should have the ability to access life-changing therapies.
Our Core Beliefs
At AscellaHealth, patients are not just part of the process—they’re why we do what we do. Every solution we build and every partnership we form is designed with the patient in mind.
Patients First, Always.
Balancing Cost and Care.
Better Stakeholder Outcomes.